- Home
- TLSA vs BOLD Comparison
TLSA vs BOLD Comparison
Compare TLSA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- BOLD
- Stock Information
- Founded
- TLSA 2013
- BOLD 2018
- Country
- TLSA United Kingdom
- BOLD United States
- Employees
- TLSA N/A
- BOLD N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- TLSA Health Care
- BOLD
- Exchange
- TLSA Nasdaq
- BOLD Nasdaq
- Market Cap
- TLSA 87.8M
- BOLD 81.0M
- IPO Year
- TLSA 2000
- BOLD 2024
- Fundamental
- Price
- TLSA $1.20
- BOLD $2.95
- Analyst Decision
- TLSA
- BOLD Strong Buy
- Analyst Count
- TLSA 0
- BOLD 3
- Target Price
- TLSA N/A
- BOLD $23.00
- AVG Volume (30 Days)
- TLSA 145.8K
- BOLD 57.8K
- Earning Date
- TLSA 05-10-2024
- BOLD 11-11-2024
- Dividend Yield
- TLSA N/A
- BOLD N/A
- EPS Growth
- TLSA N/A
- BOLD N/A
- EPS
- TLSA N/A
- BOLD N/A
- Revenue
- TLSA N/A
- BOLD N/A
- Revenue This Year
- TLSA N/A
- BOLD N/A
- Revenue Next Year
- TLSA N/A
- BOLD N/A
- P/E Ratio
- TLSA N/A
- BOLD N/A
- Revenue Growth
- TLSA N/A
- BOLD N/A
- 52 Week Low
- TLSA $0.41
- BOLD $2.82
- 52 Week High
- TLSA $1.74
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- BOLD N/A
- Support Level
- TLSA $0.83
- BOLD N/A
- Resistance Level
- TLSA $0.92
- BOLD N/A
- Average True Range (ATR)
- TLSA 0.09
- BOLD 0.00
- MACD
- TLSA 0.03
- BOLD 0.00
- Stochastic Oscillator
- TLSA 84.52
- BOLD 0.00
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.